Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 18/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 18/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8479508 | 0.95 | ITGAV (0.49) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL8483637 | 0.90 | ITGAV (0.47) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL8483640 | 0.85 | ITGAV (0.47) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL7013422 | 0.84 | ITGAV (0.45) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL20480946 | 0.80 | ITGAV (0.52) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL7013425 | 0.80 | ITGAV (0.47) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL22893988 | 0.80 | ITGAV (0.46) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL20141573 | 0.79 | ITGAV (0.44) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL7679223 | 0.79 | ITGB3 (0.49) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL20480954 | 0.78 | ITGAV (0.46) | ITGAVITGB3ITGB5ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5952341-A | VITRONECTIN RECEPTOR ANTAGONISTS FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, AND INHIBITING RESTENOSIS, DIABETIC RETINOPATHY, TUMOR, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION | MERCK & CO., INC. (US) | 1999-09-14 | — | — | US | disclosed |